A Ras-related protein and its application in tilapia's resistance to streptococcal infection

By developing Ras-related proteins and their preparations, the problem of lack of safe and efficient prevention and control measures for tilapia streptococci disease was solved, effective inhibition of alactis streptococci was achieved, and a safe and efficient biological agent was provided, which promoted loropia. The healthy development of non-fish farming industry.

CN117603328BActive Publication Date: 2024-11-05SHENZHEN RESEARCH INSTITUTE OF NORTHWEST A & F UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311591125.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-11-25
Publication Date
2024-11-05
Estimated Expiration
2043-11-25

AI Technical Summary

Technical Problem

The tilapia streptococci disease lacks safe and efficient prevention and control measures. The existing biological agents are limited in types and the prevention and treatment effect is poor, which affects the healthy development of the tilapia breeding industry.

Method used

A Ras-related protein and its application in anti-streptococcus infection in tilapia was developed. By providing Ras-related proteins, their expression vectors and recombinant bacteria, agricultural agents for preparation are prepared for the prevention and treatment of Streptococcus infection with alactis.

Benefits of technology

Ras-related proteins can significantly inhibit the growth of Streptococcus alactis, have high expression characteristics and excellent antibacterial ability, and provide a safe and efficient biological agent solution to meet the needs of the tilapia farming industry.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117603328B_ABST
    Figure CN117603328B_ABST
Patent Text Reader

Abstract

The present invention belongs to the technical field of aquatic animal molecular biology, and relates to a Ras-related protein and its application in tilapia's resistance to streptococcal infection. The present invention provides a Ras-related protein, which plays an important role in the immune defense process of tilapia's resistance to streptococcal infection. The Ras-related protein exhibits excellent antibacterial ability and high binding efficiency with Streptococcus agalactiae, and solves the technical problem of the difficulty in preventing and controlling bacterial diseases in tilapia, especially the difficulty in preventing and controlling Streptococcus agalactiae.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of aquatic animal molecular biology, and relates to a Ras-related protein and application thereof in preventing tilapia from streptococcal infection. Background Art

[0002] Streplococcus agalacliae, also known as group B streptococcus (GBS), is a Gram-positive coccus and a widespread opportunistic pathogen in nature. It is a significant pathogen of warm-water fish, affecting both marine and freshwater species. It is prevalent in water temperatures above 26°C and is generally considered a seasonal summer disease. It is a typical pathogen affecting the tilapia aquaculture industry.

[0003] Currently, there are no safe and effective prevention and control measures for tilapia streptococcosis. While the use of a certain amount of antibiotics can suppress outbreaks to some extent, the increasing resistance of Streptococcus agalactiae has led to a significant rebound in the disease upon discontinuation of treatment. The most effective treatment for tilapia streptococcosis is formalin or other broad-spectrum antimicrobials. While formalin has the strongest antibacterial effect, it has certain toxic side effects on humans and tilapia. Other broad-spectrum antimicrobials have potential mutagenic and carcinogenic effects in humans. To ensure the healthy and sustainable development of the tilapia industry, the search for and development of effective and safe biopharmaceuticals is urgent. Summary of the Invention

[0004] The present invention aims to provide a novel method for the prevention and treatment of Streptococcus agalactiae, a devastating disease of tilapia aquaculture products. Currently, chemical agents are the main preventive and control agents. Existing biological agents (such as plant extracts) are limited in variety and have poor control effects. This has become a limiting factor that cannot be ignored in the healthy development of the tilapia aquaculture industry.

[0005] Based on the above objectives, the present application satisfies the need in this field by providing a Ras-related protein and its application in treating tilapia with streptococcal infection.

[0006] In one aspect, the present invention relates to a Ras-related protein, the amino acid sequence of which is shown in SEQ ID NO: 1.

[0007] In another aspect, the present invention relates to an expression vector comprising a nucleotide sequence encoding the Ras-related protein.

[0008] In another aspect, the present invention relates to a recombinant bacterium comprising the above-mentioned expression vector.

[0009] In another aspect, the present invention relates to a recombinant Escherichia coli comprising the above-mentioned expression vector.

[0010] On the other hand, the present invention relates to the use of the above-mentioned Ras-related protein, or expression vector, or recombinant bacteria, or recombinant Escherichia coli in the preparation of a medicament for preventing and treating Streptococcus agalactiae in tilapia.

[0011] In another aspect, the present invention relates to an agricultural agent, the active ingredient of which comprises the above-mentioned Ras-related protein.

[0012] In another aspect, the present invention relates to an agricultural preparation for controlling Streptococcus agalactiae, wherein the active ingredient of the agricultural preparation for controlling Streptococcus agalactiae comprises the Ras-related protein according to claim 1.

[0013] On the other hand, the present invention relates to an agricultural preparation for preventing and treating tilapia infection with Streptococcus agalactiae, wherein the active ingredient of the agricultural preparation for preventing and treating tilapia infection with Streptococcus agalactiae comprises the above-mentioned Ras-related protein.

[0014] As a preferred embodiment of an agricultural biopharmaceutical, those skilled in the art typically process the biologically active substance or its secondary metabolites into an agriculturally acceptable formulation for application. For the use of the Ras-related proteins described herein for the control of Streptococcus agalactiae, agriculturally acceptable formulations include wettable powders, suspension concentrates, and paste-like spreads. Those skilled in the art will appreciate that, in addition to the Ras-related proteins described herein, such agricultural biopharmaceuticals may also include agriculturally acceptable carriers or adjuvants.

[0015] Illustratively, the Ras-related protein of the present invention, or the dried product (lyophilized powder) of the fermentation broth of Escherichia coli expressing the Ras-related protein of the present invention, can be prepared into conventional wettable powders or dusts or dispersible granules, and those skilled in the art are familiar with using corresponding carriers or adjuvants to complete the present invention.

[0016] For example, the Ras-related protein of the present invention, or the dried product (lyophilized powder) of the fermentation broth of Escherichia coli expressing the Ras-related protein of the present invention can be prepared into a conventional suspension. Based on conventional technical means or inspiration, those skilled in the art can easily select a suspension to prepare the corresponding carrier or auxiliary agent.

[0017] For example, the Ras-related protein of the present invention, or the dried product (lyophilized powder) of the fermentation broth of Escherichia coli expressing the Ras-related protein of the present invention can be prepared into conventional granules. Based on conventional technical means or inspiration, those skilled in the art can easily select granules to prepare corresponding carriers or auxiliary agents.

[0018] Compared with the prior art, the technical solution provided by the present invention has at least the following beneficial effects or advantages:

[0019] The present invention discovered a tilapia disease-resistant immunity-related gene, Rap1, that responds to Streptococcus agalactiae and is highly expressed in the immune response of tilapia infected with S. agalactiae. When healthy tilapia are infected with S. agalactiae, the expression level of this gene is significantly upregulated. Based on this tilapia disease-resistant immunity-related gene, the present invention obtained a Ras-related protein. Even in the presence of interference from other proteins, the Ras-related protein can bind to S. agalactiae in a concentration-dependent manner and exhibit excellent antibacterial activity against S. agalactiae. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings in the description are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0021] Figure 1 Schematic diagram of the identification results of the recombinant expression plasmid pET28a-Rap1. M1 represents DNA Marker2000Plus; lane 1 represents PCR amplification using the plasmid as a template; lane 2 represents the results of EcoR I / Xho I double enzyme digestion; lane 3 represents the results of EcoR I single enzyme digestion; M2 represents DL15000 DNA Marker.

[0022] Figure 2 The SDS-PAGE expression analysis and protein purification results of rRap1.

[0023] Figure 3 Western blot analysis results of rRap1.

[0024] Figure 4 ELISA was used to analyze the binding of tilapia rRap1 to Streptococcus agalactiae. PBS was used as the blank control group, pET-28a was used as the empty vector group, and rRap1 was used as the experimental group.

[0025] Figure 5 Western blot analysis of the binding of tilapia rRap1 to Streptococcus agalactiae.

[0026] Figure 6 The absorbance detection method was used to analyze the antibacterial ability of tilapia rRap1 against Streptococcus agalactiae.

[0027] Figure 7 The plate colony counting method was used to analyze the antibacterial ability of tilapia rRap1 against Streptococcus agalactiae.

[0028] Wherein, rRap1 represents the Ras-related protein of the present invention, and a, b, c, and d represent significant differences between groups with p < 0.05. DETAILED DESCRIPTION

[0029] The technical solutions of the present invention are described below with reference to the following examples. However, the present invention is not limited to the following examples. The experimental methods and detection methods described in each example are conventional methods unless otherwise specified; the reagents and materials described are commercially available unless otherwise specified.

[0030] Example 1

[0031] This example provides the construction, extraction and purification of a recombinant expression plasmid of Ras-related protein (hereinafter referred to as rRap1).

[0032] Tilapia (Australian tilapia) weighing an average of 20–30 g were purchased from a tilapia farm in Guangdong, China. Prior to the experiment, tilapia were cultured in a circulating water system for at least 2 weeks to acclimate to the environment. The water temperature was controlled at 28 ± 2°C, and the pH was maintained at 7.0–8.0. Dissolved oxygen, hydrogen sulfide, and nitrite levels were checked regularly. Healthy tilapia were anesthetized with MS-222 (South ranch, China), and then dissected to collect relevant tissues, including head and body kidneys, heart, brain, spleen, liver, intestine, gills, skin, muscle, and peripheral blood. Tissues from three healthy tilapia were pooled in a centrifuge tube, and all collected samples were stored at −80°C.

[0033] Total RNA from each tissue was extracted using the Trizol lysis method and converted to cDNA using a cDNA reverse transcription kit (Yugong Biolabs, China). The experimental steps and reaction system are summarized as follows: 3 μL of total RNA, 1 μL of dsDNase, and 1 μL of 10× dsDNase buffer were mixed in an enzyme-free PCR tube, and enzyme-free water was added to a total volume of 10 μL. The tube was incubated at 37°C for 2 minutes and 65°C for 2 minutes. Then, 4 μL of ALL-in-One-first-strand Synthesis Master Mix was added to the reaction solution, and enzyme-free water was added to a total volume of 20 μL. The reaction was stopped by incubation at 50°C for 15 minutes and at 85°C for 5 minutes. The resulting cDNA was stored at -80°C until use.

[0034] Based on the tilapia disease resistance-related immune gene Rap1 (nucleotide sequence shown in SEQ ID NO:2, encoding rRap1), Rap1-F and Rap1-R-specific primers (containing EcoRI and XhoI sites, Table 1) were designed using Oligo 7 software and sent to Shanghai Bioengineering for synthesis. Rap1 was then amplified using the head kidney cDNA described above. PCR products were examined by 1% agarose gel electrophoresis, and the target gene fragment was recovered using a gel extraction kit and ligated into the pMD-19T vector. The ligation product was transformed into DH5α competent cells, inoculated in LB solid medium (containing ampicillin), and cultured at 37°C for 12 hours. Positive clones were sequenced and analyzed by Shanghai Bioengineering.

[0035] The pMD19T-Rap1 plasmid was extracted from the positive clone DH5α(19T-Rap1) identified by sequencing according to the instructions of the plasmid extraction kit (AG, HuNan, China). This plasmid was then ligated with the pET-28a vector (stored in our laboratory) after double digestion with EcoRI and XhoI to generate the pET28a-Rap1 plasmid, which was then transformed into BL21 competent cells (Tsingke, Beijing, China). The transformed BL21(28a-Rap1) strain was plated onto LB solid medium supplemented with 1% kanamycin and cultured in an inverted manner at 37°C. Positive clones were identified by PCR and sequenced by Shanghai Biotechnology. The positive clones with the correct sequence were then inoculated into sterile Kan-LB medium for induced expression. When the OD600 reaches approximately 0.4–0.6, add isopropyl β-D-thiogalactopyranoside (IPTG) to the liquid culture medium and induce at 37°C, 180 rpm for 5 h. Then, centrifuge at 11,000 rpm for 10 min, and resuspend the pellet in 30 mL of 10 mM PBS. Ultrasonication is then performed on ice, and the fractions are collected for analysis of target protein expression distribution by SDS-PAGE. Protein band size is verified by Western blot.

[0036] Table 1 Experimental related primers

[0037] Primers Sequence (5'-3') Rap1-F GGAATTCATGCGCGAGTACAAGCTTGTG Rap1-R CCGCTCGAGTTAGAGCAGTGTGCAACTTGAC

[0038] The identification results of the obtained recombinant expression plasmid pET28a-Rap1 are as follows Figure 1 As shown, M1 represents DNA Marker2000Plus, lane 1 represents PCR amplification using plasmid as template, lane 2 represents EcoR I / Xho I double enzyme digestion identification result, lane 3 represents EcoR I single enzyme digestion identification result, and M2 represents DL15000 DNA Marker. Figure 1It can be seen that pET28a-Rap1 has been successfully constructed. The expression of recombinant protein rRap1 was detected by SDS-PAGE and Western blot. Figure 2 It can be seen that SDS-PAGE analysis showed that rRap1 was expressed in the form of inclusion bodies with a size of approximately 25kDa. Figure 3 It can be seen that rRap1 can specifically bind to mouse anti-His antibody and has a band of the expected size. The above results indicate that rRap1 has been successfully expressed and purified.

[0039] Example 2

[0040] This example provides a functional verification test of rRap1.

[0041] The binding efficiency of rRap1 and Streptococcus agalactiae (isolated from diseased tilapia, sourced from a tilapia farm in Guangdong) was as follows: Streptococcus agalactiae was cultured overnight and diluted with PBS to 1.0 × 10 8 CFU / mL, were added to a 96-well plate (100 μL / well) and coated overnight at 4°C. 5% skim milk (200 μL / well) was then added for blocking at 37°C for 2 h. rRap1 and pET-28a proteins were serially diluted to concentrations of 1000, 100, 10, 1, 0.1, and 0.01 μg / mL and incubated in the corresponding wells at 37°C for 2 h to allow protein binding to bacteria. A 10 mM PBS solution was used as a control. Mouse anti-6×His monoclonal antibody (1:2000 dilution) and HRP-conjugated goat anti-mouse antibody (1:5000 dilution) were used as primary and secondary antibodies, respectively, for 2 h at 37°C. Between each step, the 96-well plate was washed three times with 200 μL / well of PBST. Finally, color was developed with TMB one-component colorimetric solution for 30 min in the dark, and development was terminated with 2 M sulfuric acid. The OD was measured within 30 min using a microplate reader (Thermo Scientific, USA). 450 The test results are as follows Figure 4 shown.

[0042] Depend on Figure 4 As can be seen, the OD value of the rRap1 group was higher than that of the pET-28a and PBS groups, and this trend became more pronounced as the concentration increased. These results indicate that rRap1 protein can effectively bind to S. agalactiae in a concentration-dependent manner. Furthermore, even when the pET-28a protein concentration was increased to 1000 μg / mL, the OD values ​​of the pET-28a and PBS groups remained low.

[0043] Western blot detection of the binding of rRap1 protein to bacteria: Streptococcus agalactiae was cultured to OD 600The precipitate was resuspended in sterile PBS to a concentration of 1.0 × 10 8 CFU / mL. Add 2mL rRap1 (1000μg / mL) to 3mL bacterial solution, add equal amount and concentration of pET-28a protein to the control group, and incubate in a 37℃ incubator for 2h. Centrifuge at 12000rpm for 10min to collect the precipitate. Take 40μL of the resuspended sediment and add 10μL 5× loading buffer for SDS-PAGE detection. Use mouse anti-6×His antibody (1:1000, Sangon Biotech) and goat anti-mouse IgG-HRP antibody (1:3000, Sangon Biotech) as primary and secondary antibodies, respectively, for Western blot to verify the band size. The reaction was observed by enhanced chemiluminescence kit (ECL) staining. The test results are as shown below. Figure 5 shown.

[0044] Depend on Figure 5 It can be seen that compared with the pET-28a control group, rRap1 can bind to bacteria and show corresponding bands on the membrane.

[0045] Antibacterial activity of rRap1 protein: The antibacterial activity of rRap1 protein was detected by absorbance. Briefly, Streptococcus agalactiae was inoculated into brain heart infusion broth (BHI), and then rRap1 protein (50 μg / mL) was added and incubated with the bacteria at 37°C; the control group was a mixed culture of PBS and bacteria. OD values ​​were measured at 3, 6, 9, and 12 hours after incubation. 600 , collect data for statistical analysis, and the test results are as follows Figure 6 The antibacterial activity of rRap1 protein was determined by plate count method: rRap1 protein (100 μL, 500 μg / mL) was co-incubated with an equal volume of Streptococcus agalactiae, then inoculated into 10 mL of BHI medium and cultured at 37°C for 12 h; the control group was a mixed culture of PB and S bacteria. The bacterial solution was collected and serially diluted, and the dilution concentration was selected as 10 11 Count the bacteria on the plate with 50 μL of the solution applied to each plate. Set up 3 replicates for each group. After inverted culture at 37°C for 12 hours, take photos and count the bacteria. The test results are as follows: Figure 7 shown.

[0046] Depend on Figure 6 and Figure 7 It can be seen that PBS and rRap1 protein (50 μg / mL) were mixed with Streptococcus agalactiae, and the OD 600 Varies with incubation time. Figure 6 The results showed that the bacterial concentration in the PBS group increased significantly after 6 hours of culture, and the OD value was higher than that in the rRap1 group. Figure 7The plate count results also confirmed the antibacterial ability of rRap1 protein, and the number of colonies in the rRap1-treated group was significantly lower than that in the control group.

[0047] The embodiments described above are only some of the embodiments of the present invention, rather than all of them. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention as claimed, but merely represents selected embodiments of the present invention. All other embodiments obtained without creative effort and through deduction and substitution by a person of ordinary skill in the art based on the concept of the present invention are within the scope of protection of the present invention.

Claims

1. Application of Ras-related proteins in the preparation of agents for the prevention and treatment of Streptococcus agalactiae in tilapia, It is characterized in that The amino acid sequence of the Ras-related protein is shown in SEQ ID NO:

1.

2. An agricultural agent, It is characterized in that The active ingredient of the agricultural agent comprises a Ras-related protein, and the amino acid sequence of the Ras-related protein is shown in SEQ ID NO:

1.

3. An agricultural preparation for controlling Streptococcus agalactiae, It is characterized in that The active ingredient of the agricultural preparation for controlling Streptococcus agalactiae comprises Ras-related protein, and the amino acid sequence of the Ras-related protein is shown in SEQ ID NO:

1.

4. An agricultural preparation for preventing and treating tilapia infection with Streptococcus agalactiae, It is characterized in that The active ingredient of the agricultural preparation for preventing and controlling tilapia infection with Streptococcus agalactiae comprises Ras-related protein, and the amino acid sequence of the Ras-related protein is shown in SEQ ID NO:1.